



NASDAQ: ZYXI

Investor Presentation

October 2024

Forward Looking Statement



This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Corporate Overview



Zynex is a medical technology company that manufactures and sells non-invasive medical devices for pain management, rehabilitation and patient monitoring.

- We deliver **opioid-free pain management** solutions & non-invasive patient monitoring products
- Expanding direct sales distribution channels with emphasis on productivity
- Outstanding growth, profitability & margins
 - TTM Revenue of **\$193.7 million** (4-year revenue **CAGR of 42%**)
 - TTM Gross margins **79%**
 - TTM EBITDA of **\$20.2 million**
- Pre-revenue patient monitoring business with substantially higher average selling prices
- Addressable market exceeding \$4.6 billion with high growth opportunities



NASDAQ: ZYXI

Share Price ¹	\$8.53
Market Cap ¹	\$271.6M
TTM Revenue ²	\$193.7M
TTM Gross Margin ²	79%
TTM Net Income ²	\$4.8M
Cash & Cash Equivalents³	\$37.6M
Shares Outstanding ³	31.8M
Float	15.5M
Insider Holdings	51.4%

1. As of October 22, 2024
2. TTM as of Sept. 30, 2024
3. As of Sept. 30, 2024

Corporate Purpose



Zynex provides prescription strength pain relief & exceptional service



We are committed to being the world's premier pain management provider

Our mission is to improve the quality of life of patients suffering from debilitating pain or illnesses by providing the highest technology and service standards in the electrotherapy industry.

Total Addressable Market



\$4.6B

\$950M

Pain & Rehabilitation
Incontinence Treatment
Stroke Rehab

Electrotherapy¹

- Over 1.5 billion worldwide suffering from chronic pain²
- 84% of patients were able to reduce medication use³
- 100% of revenues today

Hemodynamic Monitoring
Pulse Oximetry
Sepsis

\$3.6B

PATIENT MONITORING⁴

- >6,000 hospitals and >900,000 staffed beds in the U.S.⁵
- Over 36M annual hospitals admissions in the U.S.⁵
- Pre-revenue business today

1) Emergen Research report titled "Electrotherapy Market by treatment type, by application, by end use and by region, forecast to 2028", February 2021. \$ Market size does not include Stroke.

2) Boston University School of Public Health, "Chronic Pain and the Health of Populations", September 24, 2017.

3) Chabal, et. al. Long-Term Transcutaneous Electrical Nerve Stimulation (TENS) Use: Impact on Medical Utilization and Physical Therapy Costs Clinical Journal of Pain. The Clinical Journal of Pain. Vol 14, No 1. March 1998

4) MarketsandMarkets, "Pulse Oximeter Market, Global Forecast to 2026" May 2021; Emergen Research report titled "Hemodynamic Monitoring Devices Market", June 2021. \$ Market size does not include Sepsis

5) The American Hospital Association - Fast Facts on U.S. Hospitals, 2021

Electrotherapy Addressable Market & Product Portfolio

\$950M¹ Pain & Rehabilitation
Incontinence Treatment
Stroke Rehab

ELECTROTHERAPY



Nexwave
Pain Relief,
Muscle Rehabilitation



**Rehabilitation
Products**



Other Products
Inwave &
Neuromove

1) Emergen Research report titled "Electrotherapy Market by treatment type, by application, by end use and by region, forecast to 2028", February 2021. \$ Market size does not include Stroke.

NexWave Prescription Strength Electrotherapy



Opioid-Free Pain Treatment

- 84% of patients were able to reduce medication use¹
- Nearly half reduced medication consumption by 50%¹

Benefits

- Relieves pain, augments healing, alleviates swelling through increased blood circulation, prevents muscle disuse atrophy, relaxes muscle spasms
- **Beyond TENS:** Vastly superior performance to over-the-counter TENS devices

Capital/Consumable Business Model (“Razor Blade Model”)


- 2023: 68% of revenue from supplies

Reimbursed by Health Insurance via prescription



¹) Chabal, et. al. Long-Term Transcutaneous Electrical Nerve Stimulation (TENS) Use: Impact on Medical Utilization and Physical Therapy Costs Clinical Journal of Pain. The Clinical Journal of Pain. Vol 14, No 1. March 1998

Building a Strong Distribution Network



Patient Monitoring Addressable Market & Product Pipeline



\$3.6B¹ Hemodynamic Monitoring
Pulse Oximetry
Sepsis

PATIENT MONITORING



CM-1500/1600

FDA Cleared Noninvasive Wireless
Fluid Monitoring System

NiCO™ & HemeOx™

Laser-based Noninvasive CO-Oximeter (NiCO™)
& Total Hemoglobin Pulse Oximeter (HemeOx™)

*prototypes

Sepsis

Noninvasive Sepsis Monitor
*utility patent filed

1) MarketsandMarkets, "Pulse Oximeter Market, Global Forecast to 2026", May 2021; Emergen Research report titled "Hemodynamic Monitoring Devices Market", June 2021. \$ Market size does not include Sepsis. 2) Prototypes. 3) Utility patent filed. * Currently under development.

Patient Monitoring Product Pipeline



Hemodynamic Monitoring

Noninvasive, continuous fluid monitoring

Early Warning System

- Determines changing trend in patient condition

CM-1500

- FDA 510 (k) cleared - February 2020

CM-1600 next generation, wireless device

- FDA 510(k) cleared - June 2023
- CE mark in process



Pulse Oximetry

NiCO™

Noninvasive CO-Oximeter uses laser technology to measure hemoglobin

- Direct replacement for inaccurate LED-based technology common today

HemeOx™

Total Hemoglobin (tHb) Pulse Oximeter replaces invasive blood draws



Sepsis Monitoring

Global Health Concern

- 48M cases and 11M deaths per year, globally¹

Simplified Early Detection and Alerting


- Current methods insufficient in early detection and alerting of sepsis onset
- Prevalence of sepsis partially due to the challenge of early diagnosis

Utility Patent Filed

December 2021

¹) Company estimates based on public industry sources


Growth Trajectory




Financial Performance



Revenue (\$M)



Gross Margin (%)



2024 Guidance of \$200 million


**Consistently high gross margins
imply a defensible business model**

1) TTM as of September 30, 2024


Financial Performance



Diluted EPS (\$)



Adj. EBITDA (\$M)



Consistent profitability despite investments in a direct sales team and buildout of monitoring division

1) Note: Adjusted EBITDA reflects earnings before interest, taxes, depreciation, amortization, non-cash lease expense, non-cash lease expense, one-time severance, other income/expense and stock compensation. Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold. See appendix for EBITDA reconciliation figures

2) TTM as of September 30, 2024

Valuation

Medical Equipment Manufacturers



Company	Ticker	Share Price	Market Cap	EV	Sales		Sales Growth		P/Sales	Gross Margin	EBITDA		EBITDA MARGIN	EV/EBITDA	
					2023	2024E	24/23	4-Yr CAGR			2024E	2023		2024E	2023
Medical Equipment															
SI-Bone	SIBN	\$12.98	\$541	\$425	\$139	\$166	19%	20%	3.3x	79%	-42	-\$8	-30%	-10.2x	-53.9x
Alphatec	ATEC	\$5.38	\$756	\$1,247	\$482	\$602	25%	44%	1.3x	53%	-\$89	\$25	-18%	-14.1x	49.3x
Nevro Corp.	NVRO	\$5.15	\$192	\$159	\$425	\$403	-5%	2%	0.5x	66%	-88	-\$20	-21%	-1.8x	-8.1x
Axogen	AXGN	\$13.28	\$582	\$622	\$159	\$185	16%	10%	3.2x	80%	-\$16	\$15	-10%	-39.1x	40.7x
Angiodynamics	ANGO	\$7.27	\$295	\$246	\$328	\$284	-13%	4%	1.0x	47%	\$3	\$0	1%	72.3x	NM
Orthofix Medical	OFIX	\$16.03	\$612	\$737	\$747	\$797	7%	13%	0.8x	63%	-\$89	\$67	-12%	-8.3x	11.0x
Cutera	CUTR	\$0.70	\$14	\$365	\$212	\$142	-33%	4%	0.1x	25%	-\$146	-\$74	-69%	-2.5x	-4.9x
Average							2%	14%	1.4x				-23%	-0.5x	5.7x
Zynex Medical	ZYXI	\$8.53	\$272	\$319	\$184	\$200	9%	42%	1.4x	80%	\$15	\$31	8%	21.3x	19.3x

Management Team



Thomas Sandgaard

Founder, Chairman & CEO

- Chairman, President, and CEO of Zynex since founding the company in 1996 - In-depth knowledge of the industry and is the driving force of the company strategies.
- Previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco, and Philips.
- Most of his work has been in the areas of international sales and distribution, technology transfers, mergers and marketing management in the semiconductor, telecommunications, data communications, and medical equipment industries.



Dan Moorhead

Chief Financial Officer

- Responsible for all finance and accounting functions.
- Prior to joining Zynex, was Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from 2016 until 2017, after having served as Vice President of Finance & Administration from 2011 through 2015 and in other financial management roles from 2002-2005 and 2008-2011.
- Is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.



Anna Lucsok

Chief Operating Officer


- Previously served as VP of Reimbursement and Sales Operations with Zynex Medical, and was responsible for leading and expanding Zynex's order, reimbursement, patient experience, and inside sales support operations.
- Brings more than nine years of healthcare operations experience as well as critical knowledge of revenue cycle management and medical care collections.
- Previously held key positions with companies such as University of Colorado Hospital, and Schryver Medical.



Donald Gregg

President, Zynex Monitoring Solutions

- Customer-focused, entrepreneurial and results-driven leader at the intersection of high-tech, medical device and data science with 25+ years of successful product, marketing, P&L, and general management experience.
- Previously held leadership roles as Smith Medical's Vice President and General Manager of Infusion Systems and Medtronic's Senior Director of Product, Marketing and Business Development of Health Informatics and Monitoring.
- Prior to leading businesses in the medical device industry, spent 15+ years in the high-tech industry at Seagate Technology, Roxio, Napster, and Gateway Computers.



Steve Fox

Vice President of Sales

- Brings over 15 years of management and sales experience to his role at Zynex.
- Prior to becoming VP of Sales, he was the Regional Sales Manager (RSM) for the Texas, Great Lakes and Mid-Central Regions throughout 2020 and much of 2021.
- This Metropolitan State University of Denver alumni holds a Bachelor's Degree in History with a minor in Secondary Education and is extremely passionate about coaching, building a strong work culture at Zynex, and leading his teams to success.
- Also spends time as an Executive Board Member of the OneGoat Foundation, a charity organization dedicated to supporting First Responder Foundations across the country.

Investment Highlights



Company valued on established electrotherapy business. Patient monitoring business is pre-revenue with transformative growth potential

Outstanding financial performance

- 42% Revenue CAGR from 2019 – 2023 (\$45.5M → \$184.3M)
- 17% EBITDA CAGR from 2019 - 2023 (\$12.1M → \$22.3M)
- SaaS-like gross margins of ~80%
- Solid balance sheet: \$37.6 million in cash

Growing and productive direct sales team with target of 800 regions averaging at least \$1 million in annual revenue per rep

Insiders own ~51.4% of outstanding shares



Investor Relations

Quinn Callanan, CFA or
Brian Prenoveau, CFA
MZ Group
949-694-9594
ZYXI@mzgroup.us

Company Contact

Dan Moorhead
Chief Financial Officer, Zynex
ir@zynex.com

www.zynex.com

9655 Maroon Circle, Englewood, CO 80012

EBITDA Reconciliation



\$ in thousands	For the Three Months Ended Sept 30,	
	2024	2023
Adjusted EBITDA:		
Net income	\$ 2,382	\$ 3,594
Depreciation and Amortization ¹	478	401
Stock-based compensation expense	770	654
Interest expense and other, net	625	290
Change in value of contingent consideration	--	245
Non-cash lease expense ²	--	751
Income tax expense	795	1,356
Adjusted EBITDA	\$ 5,050	\$ 7,291
<i>% of Net Revenue</i>	10%	15%

Use of Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). Adjusted EBITDA in this release represents net income plus interest expense, tax expense, depreciation, amortization, other income/expense, non-cash lease expense, restructuring/severance and stock compensation. The Company's management believes this non-GAAP financial measure is useful to investors and lenders in evaluating the overall financial health of the Company in that it allows for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP. The following is a reconciliation of GAAP to Non-GAAP financial measures provided in this presentation.

\$ in thousands	For the Years Ended December 31,					
	2023	2022	2021	2020	2019	2018
Adjusted EBITDA:						
Net income	\$ 9,732	\$ 17,048	\$ 17,103	\$ 9,074	\$ 9,492	\$ 9,552
Depreciation and Amortization ¹	1,660	1,648	925	742	253	189
Stock-based compensation expense	2,296	2,342	1,630	2,681	820	370
Restructuring/severance ⁴	-	-	318	-	-	-
Interest expense and other, net	1,055	440	95	96	(875)	154
Change in value of contingent consideration	(2,854)	300	-	-	-	-
Non-cash lease expense ²	1,340	1,165	1,428	-	-	-
Non-cash receivables adjustment ³	6,183	-	-	-	-	-
Income tax expense	2,847	5,150	5,168	1,079	2,449	664
Adjusted EBITDA	\$ 22,259	\$ 28,093	\$ 26,667	\$ 13,672	\$ 12,139	\$ 10,929
<i>% of Net Revenue</i>	12%	18%	20%	17%	27%	34%

1) Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold.

2) Amount expensed under building lease agreements in excess of cash payments due to abated rent.

3) Amount of non-recurring reduction in net revenue, related to slow collecting receivables.

4) Severance of former COO Giuseppe Papandrea which was fully expensed in Q1-2021